Trial Profile
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms ALT GIST
- 05 Jul 2023 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.
- 05 Jul 2023 Planned primary completion date changed from 1 Dec 2019 to 31 Dec 2023.
- 01 Sep 2022 This trial has been Discontinued in Denmark, according to European Clinical Trials Database record.